Improving immunotherapy response after disease progression
Tissue, plasma testing needed to guide treatment decisions
Research focuses on fusing genomics, immuno-oncology revelations
Role of immunotherapy after progression remains unclear
Single tisagenlecleucel infusion effective in relapsed or refractory B-cell ALL
Consolidative transplant after CAR T-cell therapy shows promise in certain ALL patients
Data emerging to possibly identify new mechanisms of action in melanoma
Debate between immunotherapy, targeted therapy exists in adjuvant melanoma
Reliable model needed to identify effectiveness of combination approaches in head, neck cancer
Recurrent, metastatic head and neck cancer treatment is challenging with only few available options
More inclusive eligibility criteria needed in immunotherapy trials
Collaboration plays a role in identifying, managing immunotherapy toxicities
Practical considerations for assessing response, managing toxicities
Case Examples of Immune-Related Side Effects
Basic Immunology for the Non-Immunologist
Identifying, incorporating biomarkers in immuno-oncology
What is "adoptive T-cell therapy"?
Which tumor types are currently best treated with CAR T therapy?
How do you believe the use of CAR T cells will transform cancer therapy?
What obstacles are present in developing effective CAR T therapies?
How do cancer vaccines function?
What challenges are presented by finding reliable biomarkers?
How can immune-related biomarkers guide patient selection?
What are neoantigens?
How are tumor-specific neoantigens identified?
What are some of the new areas of immuno-oncologic therapy research?
What are the the different types of checkpoint inhibitors and how do they function?
Please discuss currently approved immunotherapeutic agents in melanoma.
Can you describe the different types of cancer immunotherapy?
Please discuss cytokines and their several functional groups.
Please discuss currently approved immunotherapeutic agents in head and neck cancers.
Please explain the cancer-immunity cycle.
Please discuss currently approved immunotherapeutic agents in lung cancer.
What are the different types of molecular testing and how do they aid in treatment selection?
Please describe the difference between naked monoclonal antibodies and bispecific antibodies.
What challenges are presented with identifying biomarkers predicting clinical benefit in the context of checkpoint inhibitors?
Please describe combination therapies used in conjunction with checkpoint inhibitors.
Please discuss antiviral vaccines and therapeutic cancer vaccines.
How should oncologists talk to patients about the differences between immunotherapy vs. chemotherapy?